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Background: PMTCT has become freely available in many African countries however 
the impact of these interventions at the population level has not been widely estimated. 
 
Aim: The aim of this study was to estimate the proportion of HIV infected/exposed 
mother and infant pairs who received the appropriate prophylaxis. 
 
Methods: Cord blood specimens were collected anonymously from women delivering 
in 10 facilities in the Free State from November 2007 to April 2008. Collected 
specimens were tested for antibodies to HIV. Specimens found to be seropositive were 
tested for the presence of nevirapine using chromatography. All PMTCT sites used 
single dose nevirapine as the minimum prophylaxis, a few used dual therapy including 
zidovudine and nevirapine and some included nevirapine-based HAART for eligible 
women. Information was also collected from the clinical records. Maternal PMTCT 
coverage was determined through cord blood chromatography and infant coverage was 
determined from documentation of receipt on the clinical records.  
 
Results: 1619 specimens were collected from women who gave birth to live infants 
were collected and tested (3.6% collection rate). 472 specimens tested positive for HIV 
antibodies on cord blood testing giving an HIV prevalence of 29.2% (95% CI 26.9-
31.4%). Only 45.8% (95% CI 41.2-50.4%) of the 472 live infants born to HIV-infected 
mothers received both the maternal and infant doses of ARV prophylaxis. Reasons for 
failed dosing included, pre-test counseling not offered, refused testing, positive test 
result not received, prophylaxis was not dispensed, mother did not adhere and infant did 
not receive the prophylaxis dose.  
 
Conclusion: This study showed that coverage in the Free State Province is poor despite 
the national expansion of PMTCT services to all antenatal sites. Failures occurred at 
each step of the PMTCT cascade and resulted in low coverage. Interventions should be 
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Vertical transmission of HIV is the main source of HIV infection in children under 15 
years. In 2008 sub-Saharan Africa accounted for 90% of all new infections in children 
worldwide (UNAIDS/WHO. 2009c). In an effort to decrease vertical transmissions, 
PMTCT services have been integrated with antenatal care and are freely available in 
many parts of Africa. Many of these programs offer short course prophylaxis which has 
demonstrated efficacy in randomised controlled trials. Despite PMTCT being widely 
available, not all HIV-infected pregnant women access the intervention. In 2008, only 
45% of HIV infected pregnant women from middle and low income countries received 
antiretroviral treatment (ART) prophylaxis (UNAIDS/WHO. 2009d). Women need to 
follow a sequence of events in order to access a PMTCT intervention. They need to first 
access antenatal care, be offered HIV testing, accept testing, obtain the result, if HIV-
infected be offered and accept the intervention, receive the intervention, adhere to the 
dosage and their infants should be given the prophylaxis. There are many barriers to 
access the intervention including fear, denial and stigma associated with HIV and poor 
health service infrastructure. It is therefore crucial to establish at which steps failed 
coverage occurs in order to target interventions appropriately and strengthen program 
performance. 
 
The Global HIV/AIDS Epidemic 
HIV/AIDS is an important public health problem worldwide. In 2007 there were 33.2 
million people living with the virus and 7000 incident cases daily. The number of people 
living with HIV has increased rapidly since the beginning of the epidemic. In 1990 there 
were approximately 7 million people living with HIV globally, and a decade later in 
2001 this increased to 29 million. The number of new infections has declined from 3 
million in 2001 to 2.7 million in 2007. The decline in incidence has contributed to the 












have access to ART and the accumulation of on-going new infections has outweighed 
the deaths (UNAIDS/WHO. 2008b). At the end of 2008 there were more than 4 million 
people receiving ART in low and middle income countries. The ART coverage in these 
countries increased from 33% in 2007 to 42% in 2008, showing a 36% increase in one 
year. Sub-Saharan Africa had the greatest increase in coverage; from 33% in 2007 to 
44% in 2008 (ibid). 
Sub-Saharan Africa bares the bulk of the burden of this disease with 22 million people 
living with HIV/AIDS. Although current data has shown that the prevalence has either 
declined or stabilized (UNAIDS/WHO. 2007a), this region still remains the worst 
affected with 68% of all adults and almost 90% of all children living with HIV/AIDS 
(UNAIDS/WHO. 2007a). Within the region there is great variation in the rates, with 
southern Africa accounting for most of the infections. In 2007 it was estimated that 
southern African alone accounted for a third of global deaths and new infections (ibid). 
South Africa has one of the highest prevalences globally. In 2008 the prevalence among 
adults aged 15-49 years of age was 16.9% (95% CI 15.5-18.4%) (Shishana et al. 2008) 
and amongst pregnant women it was 29.3% (95% CI 28.5-30.1%) (DOH. 2009c). 
In many developing countries the high rates of poverty and an already overburdened 
health care system has made the epidemic difficult to control. HIV/AIDS further 
burdens the health care system because of the need to expand resource intensive ART 
programs and the need to retain large numbers of HIV-infected persons in care (Van 
Damme, Kober & Laga 2006). The link between HIV and poverty is complex and 
wealth and unequal income distribution are associated with HIV transmission (Veenstra, 
Whiteside 2005). Poor people are often less educated and may also engage in risky 
sexual behaviour for favours or gifts because of need (ibid). The epidemic has 












The long term macro-economic impacts of HIV are important to consider in high 
prevalence countries. There is likely to be a decline in economic growth resulting from 
reduced skilled human capital and productivity, with increased morbidity and early 
mortality from HIV (Whiteside 2002, Beck, Miners & Tolley 2001). The health care 
sector particularly is bearing the burden of the disease. There has been increased 
government expenditure for the provision of extra care, staff, treatment and support 
services for ART delivery (Veenstra, Whiteside 2005). The capacity to meet these 
demands are limited as resources (both human and financial) are inadequate, feeding 
into the poverty cycle. In Africa, many HIV infected people do not seek health care and 
thus the actual economic burden on health services may be masked, as embedded 
cultural beliefs in traditional healers, fears of stigma and denial result in low health care 
utilization. The most devastating impacts of HIV/AIDS however, are faced at the 
household level, due to loss of income and out-of-pocket payments for health care, 
increasing the likelihood of or deepening poverty (Veenstra, Whiteside 2005, Whiteside 
2002). 
HIV/AIDS among Women of Child Bearing Age 
Women are particularly vulnerable to the disease because of gender inequalities and 
economic dependency on men (Hayes 2007, De Vogli, Birbeck 2005). These socio-
economic circumstances may result in riskier sexual behaviour, sexual abuse and 
exploitation with increasing risk of exposure (De Vogli, Birbeck 2005). In 2007 there 
were 15.4 million women living with HIV globally, representing half of all HIV 
infections, with 60% living in Africa (UNAIDS/WHO. 2007a). Similarly in sub-Saharan 
Africa, 60% of the total numbers of adults infected were women. In many parts of 
Africa and the Caribbean young women (15-24 years of age) are six times more likely to 
be infected (United Nations. 2006). Gender differences are also present in South Africa. 
In 2007 it was estimated that 3.2 million women (aged 15+) were infected 













times higher than males and among the 20-24 year olds, the prevalence was 21.1% and 
5.1% in women and men respectively (Shishana et al. 2008). 
 
HIV/AIDS among Infants 
The infection rate among women of childbearing age has a direct bearing on the 
epidemiology of HIV in children. In 2007 the WHO estimated that over 400 000 
children less than 15 years of age were newly infected with the virus, mostly through 
mother–to-child transmission (MTCT) (UNAIDS/WHO. 2007a, WHO. 2004c). The 
number of children living with HIV has increased globally. In 2001 1.5 million children 
were infected and by 2007 this increased to 2.5 million worldwide. HIV/AIDS is the 
leading global cause of death in children and has increased infant and child mortality 
rates (UNAIDS/WHO. 2007a, WHO. 2004c). In 2001 the disease caused 40.3% of all 
deaths in children under five (Bradshaw, Bourne & Nannan 2003). In five sub Saharan 
high prevalence countries (South Africa, Zimbabwe, Botswana, Namibia and 
Swaziland), the mortality in children under five attributed to HIV was in excess of 
30/1000 live infants (Volmink et al. 2007). In South Africa demographic projections for 
2010 show the infant mortality rate with AIDS will be 67.4/1000 live births, and without 
AIDS, would have been 31.6/1000 live births, thus the excess mortality due to HIV was 
35.7 (Essex et al. 2002).  
 
Breastfeeding of infants by HIV-infected mothers is one of the reasons for the large 
discrepancy in transmission rates in developed and developing countries. Prior to the 
introduction of PMTCT interventions in developed countries the rate of transmission 
among non-breastfeeding populations ranged between 14% and 32%, while in 
predominately breastfeeding populations rates were between 25% and 48% (De Cock et 
al. 2000). In South Africa the rate ranges between 12% to 39% depending on 
breastfeeding and the duration of feeding and this is similar to other African countries 
(Bobat et al. 1996, Coutsoudis et al. 2001b). Member states at the United Nations 













infant infections by 50% by 2010. In order to reach this target the number of pregnant 
HIV-infected women with access to PMTCT services will have to increase. Progress has 
been made in this scale-up. In 2005 less than 10% of pregnant women requiring PMTCT 
had access to the service globally (United Nations. 2006), however by the end of 2008 
this increased to this increased to 45% in low and middle-income countries 
(UNAIDS/WHO. 2009d). The number of new infections in children globally has also 
decreased from 460 000 in 2001 to 420 000 in 2007 and the deaths due to HIV in 
children declined from 360 000 in 2005 to 330 000 in 2007(UNAIDS/WHO. 2009d). 
 
Causes of HIV/AIDS among Infants 
HIV transmission from mother to infant occurs during the intrauterine, intrapartum and 
breastfeeding periods. In non-breastfeeding populations it is estimated that 30% are 
intrauterine infections and the remaining 70% occur during labour and delivery. 
However among breastfeeding populations, 20% are intrauterine, 45-50% intrapartum 
and 30-35% postpartum infections (De Cock et al. 2000). The risk factors for 
transmission include maternal factors (low CD4+ cell count, high viral load, AIDS 
diagnosis/advanced HIV disease, high HIV viral genital secretions), obstetrical factors 
(vaginal delivery, prolonged rupture of membranes), infant factors (pre-term delivery) 
and breastfeeding (maternal advanced disease and longer duration of exposure). 
Maternal viral load has been noted to be the strongest independent risk factor (Volmink 
et al. 2007).  
 
Prevention of Mother-To-Child Transmission (PMTCT) 
MTCT can be reduced by improving access to and uptake of HIV testing and 
counselling by pregnant women followed by the use of ART as prophylaxis in those that 
are HIV-infected. ART primarily acts by reducing the viral load and thus provides 
prophylaxis to infant when HIV exposed in utero and after delivery. Other interventions 












elective caesarean section, and particularly in Africa, the promotion of safe feeding 
practices. In Africa breastfeeding avoidance may not be feasible, affordable, sustainable 
or safe. Extended prophylaxis to the infant (Bedri et al. 2008, Kumwenda et al. 2008) 
and the use of highly active antiretroviral therapy (HAART) by mothers during 
breastfeeding has been shown to reduce postnatal transmissions (Kilewo et al. 2009, 
Palombi et al. 2007). Exclusive breastfeeding (EBF) for the first six months and early 
weaning may improve child survival by providing the infant with the nutrients of breast 
milk and also reduces the risk of transmission. However this has been controversial as 
some studies have shown no overall benefit in HIV-free survival compared with longer 
breastfeeding (Kuhn et al. 2008) while others found that early weaning reduces HIV 
transmission without increasing mortality (Leroy et al. 2002). 
 
Numerous clinical trials have been conducted to show the clinical efficacy of ARV 
therapy to prevent mother-to-child transmission of HIV (Connor et al. 1994), and the 
implementation of these programs in developing countries has decreased transmission 
rates. However coverage remains low and MTCT rates are considerably higher in 
developing countries. Some high HIV prevalence settings like Zimbabwe, South Africa 
and Cameroon have managed to reduce transmission to between 6% and 15% (Coetzee 
et al. 2005, Dube et al. 2008, Ayouba et al. 2003). However a South African study 
(Rollins et al. 2007a) in KwaZulu-Natal reported a vertical transmission rate of 20.2%, 
suggesting that rates vary within countries. Other reasons for high rates include; fear and 
stigma associated with HIV, poor knowledge about HIV and PMTCT, inadequate 
maternal and child health facilities, low uptake and implementation of voluntary 
counselling and testing (VCT) services, health system failures such as drug and rapid 
test kit stock-outs and limited resources for widespread implementation (Mofenson, 
McIntyre 2000, Paintsil, Andiman 2009). Many industrialized countries have managed 
to achieve low rates through the implementation of effective strategies. For example, the 
United States has managed to reduce transmission to less than 1% (Mofenson 2004) 













sections and replacement feeding (Mofenson, McIntyre 2000). As a result field 
effectiveness, which refers to whether an intervention works among a broadly defined 
population, and takes into account the logistics and challenges of implementing the 
program in routine settings (Glasgow, Lichtenstein & Marcus 2003), closely mimics 
clinical efficacy trials conducted under ideal, experimental conditions (Stringer et al. 
2008). 
 
PMTCT Roll out in South Africa 
In 1990 the prevalence of HIV among antenatal attendees in South Africa was less than 
1% and by 2008 this increased to 29.0% (DOH. 2009c). It appears that the prevalence is 
stabilising as it has not increased since 2006. Provinces with the highest prevalence 
among antenatal attendees include KwaZulu-Natal, Mpumalanga and the Free State 
(ibid).   
 
In 2007 the UNAIDS estimated that less than 60% of HIV-infected pregnant women 
received prophylaxis. By the end of 2008 this had increased to over 70%; however 
coverage in South Africa still remains below the UNGASS target of 80%. Reasons for 
failing to achieve wide coverage include a lack of political support for HIV treatment 
and prevention programs. The former President of the country, Thabo Mbeki questioned 
the scientific evidence relating to HIV and the former Minister of Health raised concerns 
about the safety and costs of PMTCT. This delayed the introduction of PMTCT 
programs. In 1999 the only province that had started a pilot program was the Western 
Cape Province which was launched in Khayelitsha (Schneider, Fassin 2002). The initial 
regimen was zidovudine twice daily from 36 weeks until labour. During labour 300mg 
of zidovudine was given every three hours until delivery, based on evidence from the 
Thai study (Shaffer et al. 1999). Mothers who chose not to breastfeed were provided 













In 2002 the Treatment Action Campaign (TAC) brought a court action against the 
national government and the Constitutional Court ordered the universal provision of 
prophylaxis to all identified seropositive pregnant women. The National Department of 
Health implemented a pilot program in 18 sites (two in each province) (DOH. 2008a). 
Single dose nevirapine given to the mother at the onset of labour and a dose to the baby 
within 72 hours of delivery was included in the package based on evidence from the 
HIVNET 012 trial (Guay et al. 1999). Rapid HIV antibody tests were performed at 12 
months (Doherty, McCoy & Donohue 2005). 
The current WHO guidelines recommend that HIV-infected pregnant women with a 
CD4 lymphocyte count greater than 350 μ/l are provided with a combination of short 
course zidovudine and single dose nevirapine, short course zidovudine and nevirapine to 
their infants and again post delivery to the mother, a „tail‟ of zidovudine and lamivudine 
to decrease nevirapine resistance (Maheswaran, Bland 2009, WHO. 2001a). If the 
mother has advanced disease (WHO stage 4 or the CD4 count is less than 350 μ/l) the 
WHO recommends HAART be initiated as early as possible in pregnancy. In South 
Africa only women with a CD4 lymphocyte count less than 200 μ/l are initiated on 
HAART. The first line HAART regimen in South Africa for pregnant women comprises 
zidovudine, lamivudine and nevirapine. Women not requiring HAART receive 
zidovudine from 28 weeks of gestation until labour together with single dose nevirapine 
at the onset of labour. On delivery the infant is given single dose nevirapine plus 
zidovudine for 7 days. In the event that the mother received less than the required one 
month of zidovudine then the infant is given zidovudine for 28 days. 
The mother is counselled during antenatal care and after delivery on safe feeding 
options. She is either encouraged to practice exclusive breastfeeding for the first six 
months or formula feed if this is affordable, acceptable, sustainable, feasible and safe. 













At six weeks irrespective of feeding option chosen, all infants exposed to HIV are tested 
using the HIV DNA polymerase chain reaction (PCR) test. This is an antigen and not an 
antibody test, and identifies the virus in children younger than 18 months when maternal 
HIV antibodies may be present in the child. This test is conducted at 6 weeks of age as 
infants receive their first scheduled immunisation at 6 weeks in accordance with the 
WHO initiated Expanded Program on Immunisation (EPI). In routine settings the test 
has a sensitivity of 98.8% (95% CI 98.0-99.5%) at six weeks (Sherman et al. 2005). 
Testing is repeated for infants who are HIV negative at 6 weeks and who are breastfed, 
after the cessation of breastfeeding (DOH. 2008a). 
 
Rates of mother-to-child transmission in South Africa 
Studies in South Africa show that the rates of MTCT range from 8.6% to 22.3% 
(Coetzee et al. 2005, Rollins et al. 2007, Colvin et al. 2007). The Johannesburg 
Coronation Women and Children‟s study which was conducted in an urban setting 
found a transmission rate of 8.7% at 6 weeks and 8.9% at 3 months (Sherman et al. 
2004). The relatively low rate of transmission at 3 months was attributable to the small 
proportion of the women who breastfed. In another high HIV-prevalence urban setting 
in Cape-Town with a high rate of replacement feeding a similar rate (8.8%) was 
reported (Coetzee et al. 2005). Replacement feeding, high rates of caesarean sections 
and the use of zidovudine in addition to single dose nevirapine contributed to the low 
rate. On the other hand in KwaZulu-Natal transmission rates at six weeks were 20.2% 
(95% CI 17.8-23.1%) overall and 15% in those who reported to have taken nevirapine 
only (Rollins et al. 2007). In this study 14% of infected mothers reported that they had 
not taken nevirapine and almost 7% of seropositive mothers were either late 
seroconverters or received false negative results during antenatal care and thus were not 













Free State and PMTCT Services 
The Free State has one of the highest HIV prevalences in South Africa. In 2008 the 
prevalence among antenatal attendees in the Free State was 33.5% CI (95% 28.3-39.1%) 
(DOH. 2009c). The provincial PMTCT program is co-ordinated by the Maternal Child 
and Women‟s health (MCWH) directorate. In 2001 the initial pilot sites were 16 clinics 
that referred pregnant women to hospitals in Virginia and Frankfort for delivery. These 
sites were chosen to reflect the different socio-economic conditions in the province. 
During the pilot 58% of pregnant women in Virginia and 43% in Frankfort received pre-
test counselling and accepted HIV testing. There were stock outs of rapid HIV test kits 
for a period of three months in 2002 and specimens had to be sent away to a central 
laboratory for testing. This resulted in missed opportunities for PMTCT initiation since 
many mothers did not return for their results. There was also a period when nevirapine 
was not available (Doherty et al. 2003a, Doherty et al. 2003b). 
 
Reasons for low coverage included that the nurses forgot to administer the infant dosing, 
mothers did not receive nevirapine because of nevirapine stock-outs, mothers delivered 
outside the facility, and omissions on the part of the health care worker to supply the 
mother with nevirapine. At the time HIV testing was done by antibody testing at nine 
months. Forty three percent of mothers did not bring their infant for rapid testing 
between 9 and 12 months of age or, were lost to follow up. Of the 129 live infants born 
between August 2001 and March 2002 only 56 infants (43%) were tested and 21 
identified as HIV infected. In the Free State 64% of mothers‟ breastfed, the province 
with the highest rate in South Africa (Doherty et al. 2003a). 
 
In 2003 the PMTCT program was expanded to all antenatal services. This expansion 
resulted in the training of professional nurses on the PMTCT protocol, operational 
issues and safe infant feeding options. Lay counsellors were trained to provide VCT. In 
2007 the PMTCT program was evaluated in three sub-districts in the Free State as part 














 LITERATURE REVIEW 
 Prevention of Mother-to -Child Transmission of HIV 
The prevention of vertical transmission of HIV is a priority in countries with a high 
prevalence of HIV among women of child bearing age. The WHO provides a four stage 
framework for interventions to successfully reduce infections in infants. The 
comprehensive guidelines includes; primary prevention of HIV in women of child 
bearing age, prevention of unintended pregnancies in HIV infected women, prevention 
of HIV transmission to infants and the provision of care, treatment and support of 
mothers, children and families living with HIV. 
 
Strategies need to be targeted at women not infected with HIV to achieve the first and 
second goals. In many settings interventions targeted at HIV negative women during 
pregnancy are not conducted yet it is well established that acquisition of HIV infection 
during pregnancy or lactation increases the risk of transmission considerably as viral 
loads are very high during seroconversion (Semba, Neville 1999). Interventions should 
empower women with regards to their reproductive rights and choices, increase access 
to contraceptives, free condoms, VCT services and provide support systems for women 
facing gender based violence (DOH. 2008a, WHO. 2001b). 
 
Drug Therapy and Efficacy Trials 
Numerous clinical trials have shown the efficacy of different ARV regimens 
administered during the intrauterine, intrapartum and postnatal period to reduce mother-
to-child transmissions. In the United States, the ACTG076 was the first trial conducted 
to show that a long course of zidovudine starting from 14-34 weeks of gestation, 
intravenously during labour and an oral dose to the infant for 6 weeks reduced the risk 













demonstrate the efficacy of simpler, less expensive short course regimens that are 
feasible for implementation in developing countries.  
 
A randomised placebo controlled trial (RCT) in Thailand showed that short course 
zidovudine for mothers and infants halved the risk of transmission in formula fed infants 
(Shaffer et al. 1999). The RETRO study in Ivory Coast applied the same regimen to 
breastfeeding populations (Wiktor et al. 1999) and showed a 37% reduction in 
transmission at 3 months; however efficacy diminished with time due to postpartum 
infections occurring through breast milk (Wiktor et al. 1999).  
 
Although these trials demonstrated efficacy the costs of this regimen at that time limited 
its implementation in many resource constrained settings. The HIVNET 012 trial in 
Uganda therefore developed a more affordable and feasible short course protocol based 
on nevirapine. The long half life obtained in both maternal and infant plasma 
concentrations made it suitable for single dosing and subsequently would improve 
adherence. The study compared single dose nevirapine (administered to the mother at 
the onset of labour and to the infant within 72 hours of birth) with zidovudine 
(administered to the mother during labour and to the infant for 1 week) among 
predominantly breastfeeding women. The results showed that single dose nevirapine 
was both efficacious and safe to prevent vertical transmissions decreasing the risk of 
transmission by 47% at 14 to 16 weeks (Guay et al. 1999). Controversies however 
developed in relation to the conduct of the HIVNET 012 study and claims were made 
involving irregularities in record keeping and failure to adhere to procedures during the 
reporting of safety data that may have compromised the validity (Cohen 2004). 
However several studies conducted subsequently demonstrated the low toxicity and 













The findings from HIVNET 012 and the first zidovudine trials prompted the 
development of protocols that combined both regimens. The PHPT-2 in Thailand was 
among the many to demonstrate the added benefit of nevirapine and zidovudine for 
prophylaxis. The investigators conducted a double blinded three arm randomised trial 
among a predominately non-breastfeeding population. The study compared the Thai 
zidovudine regimen, given from 28 weeks of gestation, intrapartum and for one week to 
the new born infant with two other regimens. The second arm compared the addition of 
single dose nevirapine to the mother and infant and the third to the mother only. In the 
interim analysis the zidovudine only arm had a higher transmission rate than the 
nevirapine arms and the trial arm was stopped early (6.3% in zidovudine alone and 1.1% 
in the other two arms). The results of the other two arms showed that nevirapine-based 
regimens were highly efficacious with a 2.0% transmission rate in the zidovudine plus 
both maternal and infant nevirapine arm compared to 2.8% in the maternal nevirapine 
only arm (Lallemant et al. 2004). The study showed that maternal zidovudine at 28 
weeks of gestation and single dose nevirapine at the onset of labour with or without the 
infants dosing were more efficacious in reducing transmission. In contrast, the PACTG 
316 International study in developed countries showed that the addition of maternal and 
infant nevirapine to standard antiretroviral therapy had no benefit among non-
breastfeeding populations. In this study elective caesarean sections were performed for 
all women and this may have lowered the intrapartum risk considerably (Dorenbaum et 
al. 2002). 
The intrapartum and postpartum dose of nevirapine is essential for women presenting 
late in pregnancy and who may not have received sufficient zidovudine antepartum (Dao 
et al. 2007). The PETRA study assessed the efficacy of different combinations of 
zidovudine and lamivudine in three African countries among breastfeeding populations. 
Women randomised to the first arm received zidovudine and lamivudine given from 36 
weeks of pregnancy, intrapartum and for one week to their infants. Those in the second 












the third received intrapartum zidovudine and lamivudine to the mother only and those 
in the fourth received the placebo. The transmission rates were; 5.7%, 8.9%, 14.2 and 
15.3% respectively at six weeks. Intrapartum zidovudine and lamivudine alone regimens 
were less efficacious in reducing the rate of HIV transmission (PETRA study group. 
2002). The SAINT trial in South Africa compared the efficacy of maternal and infant 
single dose nevirapine to zidovudine and lamivudine given intrapartum and to the infant 
for one week. At eight weeks there were more infections in the nevirapine arm than in 
the zidovudine and lamivudine arm (12.3% vs. 9.3%) but this was not statically 
significant (p=0.11). The overall efficacy in preventing transmissions was 50.6% for the 
nevirapine group and 58.8% for the zidovudine and lamivudine group (Moodley et al. 
2003). 
Some HIV-infected mothers do not attend antenatal care and present too late in labour to 
initiate intrapartum dosing. Trials have determined the efficacy of infant dosing alone in 
the absence of maternal intrapartum and antepartum dosing. A RCT in Malawi 
compared the efficacy of nevirapine alone and nevirapine added to zidovudine among 
infants exposed to HIV whose mothers had not received the intrapartum dose. Heel-stick 
dried blood specimens from the infants were taken and tested for HIV infection at birth, 
6-8 weeks and at 3 months using nucleic acid sequence based amplification assays
(Taha et al. 2003). This test detects HIV-1 RNA even in the primary infection stage
when HIV antibodies have not developed for serological testing (Oehlenschläger,
Schwille & Eigen 1996). At birth the transmission rate was 12.1% in the nevirapine
alone arm and 7.7% in the nevirapine and zidovudine arm (p=0.03), while the overall
rate of transmission was 20.9% and 15.3% in the two arms respectively at 6 to 8 weeks
(Taha et al. 2003). Combination therapy is therefore essential in the absence of maternal
dosing. Another RCT in Malawi among breastfeeding populations compared the
efficacy of adding a weeks‟ supply of zidovudine to the nevirapine given to infants
when the maternal nevirapine was received. The results showed no difference in the rate













regimens (6.5% for nevirapine alone versus 6.9% nevirapine and zidovudine p=0.88) 
(Taha et al. 2004).  
 
Short Course Nevirapine and Resistance 
Although single dose nevirapine regimens have proved to be efficacious and well 
tolerated, there are concerns over the development of resistance in both women and 
infants. The long half life of nevirapine increases the risk of resistance. High viral loads 
and low CD4 lymphocyte cell counts have been associated with the development of 
resistance (Eshleman, Jackson 2002). This may affect the efficacy of nevirapine in later 
pregnancies and after the initiation of nevirapine as part of a HAART regimen in both 
mother and infant at a later stage (McIntyre 2005). A follow up study found that 
resistance appeared to wane with time (Eshleman, Jackson 2002, Eshleman et al. 2001), 
suggesting that efficacy is maintained for subsequent pregnancies following single dose 
nevirapine. Observational studies conducted in South Africa, Ivory Coast and Uganda 
showed that previous exposure to single dose nevirapine did not decrease efficacy for 
subsequent pregnancies (Martinson et al. 2007, McConnell et al. 2007).  
 
Eshleman et al 2001 analysed blood samples from both the women and infants from the 
HIVNET 012 study and found the rate of resistance was 18% in women and 46% in 
infants at 6 to 8 weeks of age. Possible explanations for higher rates in infants may be 
due to the increased exposure levels, since infants receive both the maternal dose and 
the dose administered within 72 hours (Eshleman et al. 2001).  
 
Nevirapine resistance not only occurs in single dose regimens but also in combination 
with other ARV drugs, however at a lower rate when drugs with shorter half lives 
protect the “tail” after nevirapine is stopped. It has been observed that the addition of 













nevirapine only and thereby reduces the likelihood for the development of resistance 
(Chaix et al. 2006). The Ditrame Plus trial evaluated the resistance rate of single dose 
nevirapine in combination with zidovudine and lamivudine together with a 3 day 
postpartum course of the latter two drugs. The resistance rate among women at 4 weeks 
postpartum was 1.14% (Chaix et al. 2006).  
 
While there may be resistance problems associated with the use of single dose 
nevirapine alone this needs to be balanced against the cost-effectiveness, efficacy and 
simplicity in resource constrained settings (Eshleman, Jackson 2002, Eshleman et al. 
2001). 
 
Treatment Guidelines and WHO Recommendations 
Single dose nevirapine is a simple and practical option to reduce MTCT in resource 
constrained settings. This regimen has several advantages. It is less expensive than 
zidovudine based regimens (Moodley et al. 2003), easy to administer and women 
presenting late during pregnancy or at delivery can be HIV tested and treated. There is 
likely to be better adherence since single dose therapy can be administered in clinic 
settings and the half life (61-66 hours) in women and in neonates (45-54 hours) is long. 
Finally, the regimen is well tolerated with very few reports of adverse events. Hence the 
WHO recommends nevirapine to both mother and infant as the minimum prophylaxis to 
be given to HIV infected women where resources may not permit the implementation of 
combination therapy (WHO. 2001b). 
 
The WHO recommends dual therapy for women in WHO stage 1-3 or who have a CD4 
lymphocyte count greater than 350µ/l, starting with zidovudine from 28 weeks of 
gestation, lamivudine and zidovudine plus single dose nevirapine during labour, 
followed by lamivudine and zidovudine for one week for the mother, and single dose 













WHO stage 4 or WHO stage 3 and CD4 count less than 350 µ/l or WHO stage 1 or 2 
and CD4 count of between 200 and 350 µ/l the WHO recommends HAART. First line 
regimen is zidovudine, lamivudine and nevirapine (Dao et al. 2007). 
 
Breast Feeding Avoidance 
Breast milk remains one of the most important routes of MTCT in many resource 
limited settings. It has been estimated that 50% of all HIV paediatric infections occur 
through breastfeeding (WHO. 2004c). Clinical trials such as the RETRO-CI study in 
Ivory Coast found the efficacy of the PMTCT regimen decreased with time, due to the 
effects of breastfeeding. At 3 months of age efficacy declined from 44% to 37% (Wiktor 
et al. 1999) and by 24 months, had decreased to 23% in populations that continued to 
breastfeed (Leroy et al. 2002). Likewise in the PETRA study efficacy decreased by 18 
months primarily as a result of postpartum infections (PETRA study group. 2002). The 
major risk factors associated with transmission during this period include long duration 
of feeding, mastitis and cracked nipples and sores in the mouth of the child. High 
maternal viral load due to recent seroconversion or late stage of disease results in 
elevated breast milk viral load and increased rates of transmission (Semba, Neville 
1999, UNICEF 2009, Rousseau et al. 2003). In Kenya, a ten-fold increase in breast milk 
viral load was associated with a 2 fold increase in the risk of transmission (Rousseau et 
al. 2003). It has not been fully established whether infection occurs through cell free 
virus or through HIV-infected cells (Rousseau et al. 2003, Newell 2006). 
 
Studies have demonstrated that the avoidance of breast milk eliminates these postpartum 
infections. An early randomised controlled study in Kenya found a higher probability of 
HIV infection in breastfed infants than in formula fed infants (Nduati et al. 2000). 
Similarly, the MASHI trial in Botswana showed decreased HIV transmission among 














Formula or replacement feeding may not be feasible, affordable, acceptable, sustainable 
or safe in many developing countries (WHO. 2004c). Breastfeeding is beneficial 
because of the immunological and nutritional properties that are necessary for growth 
and development. In areas where the availability of clean water is limited, the excess 
morbidities and mortalities associated with formula feeding is of concern. For example, 
in many of the trials higher mortality rates were reported among infants who were 
formula fed. A cohort study in KwaZulu-Natal found that mortality rates more than 
doubled in replacement fed infants as compared to exclusively breastfed infants (15% 
vs. 6%) (Coovadia et al. 2007). The MASHI trial, also found mortality rates were higher 
in formula fed infants by seven months (9.3% vs. 4.9% p=0.003), with the most 
common causes of mortality related to diarrhoea and pneumonia (Thior et al. 2006).   
 
In resource constrained settings, EBF and early weaning have thus been proposed as a 
strategy to reduce postnatal transmissions and still offer the benefits of breast-milk. EBF 
refers to the consumption of only breast milk until six months of age, and excludes other 
milk products and any liquids or solid foods (Iliff et al. 2005). It is thought that the EBF 
method preserves the intestinal mucosa and thus presents a barrier against HIV. It 
further protects against breast complications such as mastitis where higher rates have 
been noted to occur among mothers that practice mixed feeding (Coovadia et al. 2007).   
 
The extent of the benefit of EBF is controversial since postpartum infections still occur 
through breastfeeding. A RCT conducted in Malawi found that most postpartum 
infections occurred by 6 months of age and thus the benefits of early weaning did not 
appear to be significant (Nduati et al. 2000). Similarly a longitudinal analysis in Kenya 
showed that HIV viral loads were highest in early milk as compared to mature milk, 
corresponding to a higher risk of transmission (Rousseau et al. 2003). This was also 
demonstrated in the PETRA study where most infections occurred through breastfeeding 
in the first six weeks (PETRA study group. 2002). Latest evidence from the ZEBS study 












The HIV free survival at 24 months in children that were weaned at four months was 
68.4% while children that were breastfed for longer than 4 months was 64.0% p=0.13 
(Kuhn et al. 2008). Early weaning has also been associated with an increased risk of 
malnutrition and increased mortality and morbidity from infectious diseases giving no 
overall advantage (Kuhn, Reitz & Abrams 2009, Mofenson 2008).  
The administration of postpartum doses of zidovudine, lamivudine and nevirapine may 
reduce early postpartum transmissions due to breast milk (Kourtis et al. 2007). The 
MASHI trial showed no difference in the rates of HIV transmission between formula 
and breastfed infants at 1 month during which zidovudine was administered (Thior et al. 
2006). On the other hand the PEPI trial conducted in Malawi showed that prophylaxis 
with either nevirapine alone or nevirapine and zidovudine given from birth till 14 weeks 
of age reduced postnatal transmissions. In the control group (single dose nevirapine plus 
1 week zidovudine) HIV transmission at 9 months was 10.6% (95% CI 8.7- 12.8%), in 
the extended nevirapine group (control regimen plus nevirapine daily for 14 weeks) the 
rate was 5.2% (95% CI 3.9-7.0%) p<0.001 and in the extended nevirapine and 
zidovudine (control regimen plus nevirapine and zidovudine for 14weeks) 6.4 (95% CI 
4.9-8.3%) p=0.002 (Kumwenda et al. 2008). 
Reducing postpartum infections in developing countries still remains a challenge. There 
seems to be consensus that HIV-infected women should be given ART (Shapiro et al. 
2005) and continue to breastfeed or their infants should given prophylaxis during 
breastfeeding (Bedri et al. 2008, Kumwenda et al. 2008). 
Role of Elective Caesarean Sections  
Although maternal viral load has been noted to be the strongest risk factor for 
transmission for interuterine and postpartum infections, direct contact with the virus by 












duration (over 4 hours) of rupture of membranes and vaginal delivery are obstetrical 
factors associated with increased transmission. Caesarean section in combination with 
ARV therapy has been implemented in many developed countries as part of PMTCT. 
Evidence shows that caesarean section alone may reduce HIV transmission to infants by 
50% (Brocklehurst 2002) and when used in combination with zidovudine it decreases 
the risk to less than 1% (Kourtis et al. 2001). A randomised trial compared elective 
caesarean section with vaginal delivery and found an 83% decreased risk (Brocklehurst 
2002). In developing countries the introduction of this option on a wide scale is not 
available due to expense and lack of accessible facilities. In addition the procedure is not 
without risks. Studies conducted in developed countries found that maternal mortality 
was 5 to 25 times higher (Fiore, Newell & Thorne 2004) and morbidity was six times 
higher (Lapaire et al. 2006) after caesarean section compared to vaginal delivery. Other 
studies reported higher post operative risks among HIV positive women such as severe 
anaemia requiring blood transfusions, minor complications and infections such as 
urinary tract infections, post-caesarean endometritis and postpartum fever compared to 
HIV negative women (Fiore, Newell & Thorne 2004, Lapaire et al. 2006, Marcollet et 
al. 2002, Björklund et al. 2005). Another method to decrease HIV transmission is the 
avoidance of artificial rupture of membranes.  
Measuring Operational Effectiveness 
Interventions to prevent mother-to-child transmission of HIV have been based on 
evidence from clinical trials showing efficacy conducted under ideal conditions. 
Measures of the effectiveness of the implementation of these interventions in resource 
constrained settings are lacking and the effectiveness of PMTCT programs in many 
countries is largely unknown (Stringer et al. 2003). Weak information systems remain a 
major challenge faced in estimating effectiveness as resources to collect reliable and 













Effectiveness is defined as the extent to which a health intervention results in desired 
outcomes in response to the needs of the population. It comprises a wide range of 
variables including efficacy, inputs, quality assurance mechanisms, patient compliance 
and health behaviour factors (WHO 2001). Coverage on the other hand is a proxy used 
to measure effectiveness and refers to the proportion of the population in need of an 
intervention who actually receive the intervention. The numerator indicates the number 
of units that are receiving the health intervention and the denominator comprises the 
population that would need the intervention indicated in the numerator (ibid). Utilisation 
and access (which includes accessibility, availability, affordability and acceptability) are 
other closely related terms linked to coverage and may be considered determinants of 
effective coverage (ibid).  
 
Using the assumption that the clinical benefits of ARV for the prevention of mother-to-
child transmissions will rebound to a mother and infant population that access the 
intervention appropriately, PMTCT program coverage can be evaluated (Stringer et al. 
2008). The PMTCT cascade consists of a sequence of events that must occur for 
prophylaxis to be administered and serves as a mechanism in which to measure 






















Figure 1 PMTCT coverage cascade. Source (Stringer et al. 2008) 
 
 Figure 1 shows the events which must occur in order for PMTCT to be delivered. A 
pregnant woman must attend an antenatal care facility, be offered VCT, accept testing, 
receive the test result, if infected be offered prophylaxis, agree to ARV prophylaxis, 













al. 2008). The degree to which these events occur gives an indication of program 
performance and hence coverage. Attrition may occur at each step resulting in reduced 
coverage and program effectiveness. A study in rural Malawi showed that 55% of HIV 
positive mothers were lost to follow up by 36 weeks of pregnancy, when nevirapine was 
dispensed, and by delivery this increased to 68%. Thus, only 32% of HIV 
infected/exposed mother-infant pairs received nevirapine prophylaxis (Manzi et al. 
2005). In this study the high attrition was attributed to the long distances women had to 
travel to access clinics and multiple visits required. Home deliveries and traditional birth 
attendees‟ sites were common in the district and this contributed to the low coverage 
(ibid). 
Studies conducted in routine settings suggest that demographic factors are associated 
with coverage. An increase in mothers‟ age, a higher level of education, an increase in 
the number of antenatal visits, living with a partner and delivering via caesarean section 
as compared to vaginal deliveries are some factors found to be positively associated 
with coverage (Peltzer et al. 2008, Albrecht et al. 2006, Bii et al. 2007, Kiarie et al. 
2003).  
 
Women need to access antenatal care to access PMTCT interventions. In most places in 
Africa services are widely available and freely accessible. The majority of women in 
Africa therefore access these services (Maheswaran, Bland 2009, Myer, Harrison 2003, 
Luo et al. 2007, Moses et al. 2008). In 2008 92% of pregnant women in South Africa 
accessed antenatal care (UNICEF, 2008). However some women may not attend 
antenatal care or attend few visits late in pregnancy and this may not be adequate to 
complete the steps required to receive full prophylaxis (Maheswaran, Bland 2009, Myer, 
Harrison 2003). Lack of physical access is regarded as a major barrier to access 
antenatal care especially in remote rural settings (Myer, Harrison 2003, Tanser, 














VCT is a crucial entry point to the PMTCT program. VCT uptake varies across settings. 
The Ditrame Plus study found 66% of women accepted HIV testing when HIV testing 
was on site (Ekouevi et al. 2004). In the Gulu District of Uganda, an area that faces civil 
unrest, the VCT acceptance rate was less than 60%. Another study in Burkina-Faso 
found acceptability to be very low (18%) (Pignatelli et al. 2006) .  
 
“Opt out” as opposed to the traditional „opt in‟ has improved testing coverage. With 
“opt in” women are given counselling and asked if they wish to be tested. With “opt 
out” women are informed about testing and are routinely tested unless a women 
specifically refuses to be tested (Doherty, McCoy & Donohue 2005, Manzi et al. 2005). 
In Zimbabwe, a country with high HIV prevalence there was 79% acceptance with “opt 
out” (Perez et al. 2006). Similarly in Botswana, in a before and after study, the 
percentage of women tested increased from 76% to 95% and the percentage of those 
who received their test result increased from 72% to 82%. After five years of on-site 
testing the percentage of women delivering in regional hospitals who knew their status 
increased from 47% to 78% following the implementation of „opt- out‟ VCT (Creek et 
al. 2007). Although this method has achieved successful results, there are concerns that 
HIV infected women may become victims of stigmatisation and gender based violence 
upon disclosure of their status to their partners (Pignatelli et al. 2006). 
 
Giving PMTCT to all women irrespective of HIV status is another strategy that has been 
proposed to overcome the low uptake of VCT. The universal access approach would 
increase uptake since pregnant women would not need to learn of their HIV status, in 
addition this approach would be suitable for settings where VCT is not available such as 
areas experiencing wars and conflict (WHO 2001b, Stringer et al. 2003). Using an RCT 
cross over design in Zambia, the investigators compared the universal strategy to the 
targeted strategy of giving prophylaxis to HIV positive women identified through VCT. 












without testing, was higher compared to infected women who accepted testing and 
received the intervention (70% vs. 59%; p <0.001).  
However a potential disadvantage to giving nevirapine to women who do not know their 
status is that adherence may be compromised since these women may not fully perceive 
the actual benefits of the prophylaxis as compared to those who know that they are HIV 
infected (Sint et al. 2005, Stringer et al. 2003). In this study non-adherence was higher 
in the universal arm compared to the targeted arm (39% versus. 26%) (Stringer et al. 
2003). Resistance in the mother and the risk of toxicity especially in HIV uninfected 
women are also concerns. VCT services should be integrated with antenatal care not 
only for the prevention of infant infections but also to educate, support and refer those 
mothers identified as HIV-infected and to reinforce HIV prevention in those who are not 
infected. Failing to offer VCT to pregnant women would therefore not achieve this 
(WHO 2001b, Stringer et al. 2003).  
Notwithstanding these disadvantages and the fact that the universal approach would 
only be effective for intrapartum transmissions, this may be the only suitable, feasible 
and safe approach in some settings. In places where counselling and testing is of high 
quality and accessible, the targeted approach is the method of choice. In other settings 
the combined approach may be a more realistic to reduce MTCT as it incorporates both 
strategies. In this case, women accessing antenatal care are offered VCT in the 
conventional targeted way, and those who do not wish to be tested are provided with 
treatment through mass administration (WHO 2001b, Stringer et al. 2003).  
In many settings women who participate in VCT do not return and obtain their test 
results. In a recent cohort study in rural KwaZulu-Natal, only 57% of women who 
accepted to be tested returned for their results (Mkwanazi et al. 2008). Similarly, in 












likely to be HIV positive, reflecting a crucial missed opportunity for prevention (Kiarie 
et al. 2000). Rapid HIV testing with same day result has been associated with increased 
uptake and enrolment into the program (Pignatelli et al. 2006, Pai et al. 2007). However 
even with rapid testing women may be given the option to return at a later date for the 
results (Maheswaran, Bland 2009). In KwaZulu-Natal a cohort study showed that 
women were more likely to return at a later date for their results than receive them the 
same day (65% versus 50% p<0.001) (Mkwanazi et al. 2008). Women may need time to 
assess and determine the implications of obtaining the result and the quality of 
counselling may have been poor (Mkwanazi et al. 2008). Another study in an urban 
setting in Ivory Coast conducted over a two year period to determine the acceptability of 
rapid testing, found that despite a high acceptance rate (89.4%), a quarter of women did 
not return for their results (Ekouevi et al. 2004). Similar findings were reported in 
Buhera, a rural in District in Zimbabwe, where the acceptance rate for testing was very 
high (92.9%) but return rate for those who decided to test was 74.3% (Perez et al. 2004). 
In order for an identified pregnant HIV-infected woman to receive the PMTCT 
intervention she needs to be given the prophylaxis from the antenatal facility. Less than 
60% of HIV infected women were provided with nevirapine in an Eastern Cape cohort 
that was followed (Peltzer et al. 2008). In Mombasa Kenya almost 50% of women who 
received a positive test result did not return to the clinic to collect the prophylaxis 
(Temmerman et al. 2003).  
Further attrition occurs when HIV-infected women do not adhere to the prophylaxis. 
Maternal adherence is defined as the proportion that actually take the medication 
(Stringer et al. 2005). Factors associated with non-adherence include low education 
levels, home deliveries and referral to a tertiary hospital (Albrecht et al. 2006, Bii et al. 
2007). The length of time between taking the medication and the birth of the infant is 
also critical to ensure that optimal therapeutic plasma levels are achieved to reduce the 













hour before delivery (Stringer et al. 2005, Albrecht et al. 2006). The SAINT study found 
that intrapartum transmissions were three times higher among women that had ingested 
the tablet less than 2 hours prior to delivery. Similarly the HIVNET 012 trial found that 
women who took nevirapine less than 1 hour before delivery had significantly lower 
cord blood concentrations than those who took it more than hour before delivery. 
Mothers of HIV uninfected infants reported a longer time interval between ingestion and 
delivery compared to mothers of HIV infected infants diagnosed between birth and 6 to 
8 weeks (Jackson et al. 2006).  
Infant adherence rates are higher than maternal because in most settings the first dose is 
given in the facility by the nursing staff. The evaluation of pilot sites in South Africa 
showed that almost all the infants (99%) identified received nevirapine syrup (Doherty, 
McCoy & Donohue 2005). A cohort study in Durban South Africa, similarly found high 
infant adherence with almost 90% reported having been given nevirapine (Coutsoudis et 
al. 2001a). In rural Uganda although home deliveries were common 96% of the infants 
were given the nevirapine dosing within the appropriate time limits. The nevirapine 
syrup was wrapped in aluminium foil and packaged in an opaque polythene bag similar 
to the bags containing multi-vitamin syrup given to HIV negative mothers. This 
increased acceptability as this did not divulge the woman‟s HIV status to the traditional 
birth attendees and family members (Kagaayi et al. 2005). 
 
Even where participants are provided with support as in clinical trials non-adherence 
rates are high. In the Zambian Exclusive Breast Feeding Study (ZEBS) adherence rates 
were very high (94%), but only 78% received the dose within the correct time limit. 
Adherence was measured by self reports and from clinical records and this may have 
compromised validity (Albrecht et al. 2006). In Kenya 60% of rural women who 
delivered at home reported not to have taken the required dose (Songok et al. 2003). 
Women reported that they were ashamed to take medication in the presence of 
traditional birth attendees. Different findings were noted in a follow up study in Eastern 













maternal adherence (86%), was associated with disclosure of status to partner and a high 
HIV knowledge score (Peltzer et al. 2008). Similar findings were reported in Rakai 
Uganda, where 85% of HIV positive women reported taking nevirapine (Kagaayi et al. 
2005).  
 
Giving nevirapine during delivery and not to mothers prior to labour to take at the onset 
of labour, may increase adherence as it could be directly observed. In a study conducted 
in Zambia, Stringer et al achieved almost perfect adherence (99.4%) among HIV 
positive women. This approach has its disadvantages. Women who do not deliver at a 
facility do not receive the prophylaxis. Women may present late in labour and there is 
the risk of sub-optimal therapeutic concentrations (Stringer et al. 2004). This method 
could be used to improve coverage in women who were not given nevirapine or who 
forget to take the dose. Double dosing does not seem to be associated with severe 





















Study Designs Used to Measure Effectiveness 
Prospective Follow-up Study Designs 
Prospective cohort studies have been used to measure the effectiveness of PMTCT 
programmes (Ayouba et al. 2003, Songok et al. 2003, Tonwe-Gold et al. 2007, Palombi 
et al. 2007, Leroy et al. 2008). In these studies PMTCT exposed and unexposed are 
compared and HIV free survival estimates and transmission rates are obtained as the 
measure of effectiveness (Stringer et al. 2008). HIV free survival has been proposed as 
the ideal outcome indicator for the effectiveness of PMTCT interventions (Stringer et al. 
2008, Stringer et al. 2005). This measure gives an assessment of the number of children 
who are alive and negative.  
 
A cohort study in rural Kenya determined the effectiveness of short course prophylaxis 
among a breastfeeding population. The study followed a cohort of volunteer antenatal 
attendees for two years. 216 HIV infected women were included. The criteria for 
inclusion was being married, gestational period of 18-22 weeks, no life threatening 
illness and haemoglobin levels greater than 7g/dl. The HIV free survival among the 
women who reported to have taken the prophylaxis was 59.2% compared to 29.6% in 
those who had not taken prophylaxis (p<0.0002). This study may not be generalisable 
because recruitment was voluntary and women with life threatening illness and single 
women were excluded from the study. Almost 30% of HIV exposed live infants were 
lost to follow up. Validity may have been compromised if those lost to follow up were 
more likely to have been HIV-infected and died from HIV infection (Songok et al. 
2003).  
 
A cohort study in Cameroon determined the field effectiveness of nevirapine. Women 
attending antenatal care were informed of the study purpose and those who agreed to 
participate were included. At six weeks using PCR testing, the transmission rate was 
10% (95% CI 5-16%) and by 5-6 months follow up this was 13% (95% CI 7-19%) 













the results, almost 30% (n=166) had not delivered at the time of analysis (Ayouba et al. 
2003).  
 
Follow up non-randomised observational studies that compare HIV free survival and 
transmission rates of different interventions have also been conducted (Tonwe-Gold et 
al. 2007, Palombi et al. 2007, Leroy et al. 2008). In Ivory Coast a two-tiered 
effectiveness cohort study was carried out. All HIV-infected women attending antenatal 
care were enrolled. Women either received HAART or short course ARV therapy. Over 
70% of mothers breastfed for a median duration of 5.4 months. At 1 month the rate of 
transmission was 1.0% (95% CI 0.0%- 3.1%) in the HAART group and 3.1% (95% CI 
0.1-6.1%) in the short course ARV group. At 12 months this was 3.3% (95% CI 0.0-
6.9%) for the HAART group and 7.5% (95% CI 2.8%-12.3%) in the short course ARV 
group. Although loss to follow up was minimal with 86% of the live infants available 
for testing, it is likely that more of these infants died from HIV infection (Tonwe-Gold 
et al. 2007). 
 
While it is ideal to obtain HIV free survival for measuring effectiveness of PMTCT 
programs in routine settings, cohort studies have limitations which are important to 
consider. Cohort studies are expensive and complex to conduct as large numbers of 
infants and mothers need to be followed for over 6 months after cessation of breast 
feeding. In Ivory-Coast infants were followed for 12 months (Tonwe-Gold et al. 2007) 
and in rural Kenya for 24 months (Songok et al. 2003). Investigators are ethically bound 
to provide standard of care and therefore should provide the appropriate prophylaxis or 
ensure that mothers are referred for care (Ayouba et al. 2003). Hence findings may not 
be inferred to other settings as the results of these studies may be biased towards better 
outcomes. Selection bias resulting from loss to follow-up is a threat to validity as infants 
who are not retained in the cohort may die as a result of HIV-infection. In Kenya and 













Facility based cross-sectional studies can also be used to estimate program effectiveness. 
This study design is simpler and less expensive than prospective designs as data is 
collected at one point in time or retrospectively (Stringer et al. 2008). They describe the 
burden of disease and provide population based outcomes since the entire population is 
included in the study (Stringer et al. 2008). Trends over time can also be established to 
determine the effectiveness of program implementation (Stringer et al. 2008). Missing 
or incomplete data may compromise validity.   
A clinic based survey in among infants aged between 6 and 10 weeks was conducted in 
Khayalitsha, Cape Town to assess the operational effectiveness of the PMTCT 
programme. The study used clinic registers to identify all HIV-infected mothers and 
their exposed infants were tested. Initially only zidovudine was provided but during the 
study there was a change to dual therapy of zidovudine and nevirapine. This improved 
PMTCT coverage as women who missed or did not receive sufficient zidovudine had 
the benefit of nevirapine during labour and delivery. The transmission rate was less than 
10%. In this study 24% of mothers who had not received sufficient zidovudine dosing 
before delivery received nevirapine and only 3% had not received any PMTCT 
intervention. Reasons for this low rate included a high uptake of VCT and over a quarter 
of the infants were delivered by elective caesarean. The authors commented that as 
replacement feeding was common postpartum infections would have been low. 
However the study had a number of limitations; almost 20% of mother infant pairs 
enrolled in the PMTCT program were lost to follow up at the six week follow up visit 
when infant HIV testing was conducted. This could have biased the result, particularly if 
the infants who were lost to follow up were more likely to have been HIV-infected or to 
have died from HIV infection (Coetzee et al. 2005). Therefore a strategy that will pick 












Using Cord Blood Specimens 
Anonymous cord blood specimens can be collected and tested for HIV antibodies from 
all women delivering in facilities in order to measure the effectiveness of PMTCT 
interventions. Specimens found to be positive are then tested using chromatography to 
detect nevirapine. Information from clinical records can be collected to determine if the 
infant received nevirapine. Coverage is the proportion of mother-infant pairs with HIV 
antibody positive cord blood with confirmed receipt of maternal and infant prophylaxis. 
This method yields a valid coverage estimate because all women who deliver in 
facilities are included in the study as opposed to only those who consent (Ayouba et al. 
2003, Songok et al. 2003). This method has other advantages. The use of cord blood 
specimens allows for verification of maternal adherence instead of relying on self 
reports. In Zambia a RCT found that nevirapine was not detected in the cord blood 
specimens of 28% of women who reported they ingested the dose (Stringer et al. 
2003b). Nevirapine is rapidly absorbed and crosses the placenta easily and is thus easily 
detected through chromatography analysis (Mirochnick et al. 1998). Antibody 
serological testing is also cheaper and easier to conduct than infant PCR testing.  
In Zambia a cross-sectional PMTCT effectiveness study was conducted among 10194 
women delivering in 10 public facilities using anonymous cord blood specimens to 
detect HIV antibodies and nevirapine. From the population of HIV exposed infants in 
the surveillance program, only 30% received the PMTCT package (both maternal and 
infant dose). Failed coverage occurred along the entire cascade, HIV positive mothers 
were not offered VCT (18%) or declined testing (27%). At later stages, significant 
attrition occurred due to non-compliance as more than 32% of women who were given 
nevirapine did not actually ingest the tablet at the onset of labour (Stringer et al. 2005). 
6% of mothers who were identified as negative during pregnancy were positive at 













Cord Blood Testing to Estimate Prevalence 
Anonymous cord blood HIV antibody testing also facilitates the accurate estimation of 
HIV prevalence because all women who deliver in facilities are tested. There is no need 
to obtain consent and thus those who might not have consented will be included. In most 
settings, the HIV prevalence is estimated from women who accept testing during 
antenatal care (Reithinger et al. 2007, Mpairwe et al. 2005). Women who consent to 
HIV testing may have a different HIV prevalence than those that reject but are 
anonymously tested. For example in Uganda, women who underwent VCT had higher 
HIV prevalence to those who refused but were anonymously tested (20% versus 11%), 
since women that considered themselves to be at risk for infection were more likely to 
accept VCT (Mpairwe et al. 2005). In Lusaka, women who refused testing during VCT 
were more likely to be positive than those who accepted. Programs which estimate HIV 
prevalence from women who accept testing during VCT may underestimate the true 


















Objectives of the Study 
Primary objective 
 To determine PMTCT coverage in women delivering at public sector facilities in 
the Free State.  
Secondary objective 
 To determine the prevalence of HIV at the time of delivery in Free State health 
facilities 
 To determine if the prevalence of HIV differed amongst women who refused and 
those who accepted HIV testing during antenatal care in the Free State 
 To determine factors associated with maternal adherence (nevirapine detected in 















CHAPTER III  
SUBJECTS AND METHODS 
 
Description and Background of Study Community 
The Free State covers an area of about 129,480 km2 and has a population density of 23 
people per km2. This large and sparsely populated area is the third largest province in 
South Africa and lies between the Vaal River in the North and the Orange River in the 
South. About 6.8% of the total South African population lives in this province. The 
province is divided into five districts namely; Fezile Dabi, Thabo Mofutsanyane, 
Motheo, Xhariep and Lejweleputswa. The provincial capital, Bloemfontein is located in 
the Motheo District. Thabo Mofutsanyane is the largest district, with almost 30% of the 
population in the province living in this district, followed by Lejweleputswa and Motheo 
with just over 25% of the inhabitants. The majority of the population is African (89.6%), 
9.9% white, 3% coloured and only 0.1% Asian. Most people (72.8%) live in urban 
areas, with almost 20% living in Metropolitan areas and 50% in small towns (Jacobs& 
Punt, 2009, DOH, 2009b, Davis& Tavasci, 2006). 
 












Nationally this province contributes about 5.5% to the GDP. Agriculture and mining are 
the major economic activities. Mining provides most employment opportunities, and 
produces about 30% of South Africa‟s total gold output. The rich fertile lands allow for 
agricultural activity. Many African households are involved in small scale subsistence 
farming. For commercial purposes, whites are generally the farm owners and the 
wealthiest while the Africans who generally provide labour, are the poorest (Jacobs, 
Punt 2009, Davis, Tavasci 2006).
The official unemployment rate for the first quarter of 2009 in the Free State was 25.4% 
(Statistics South Africa. 2009b). This rate was higher than the national average of 23.1% 
during the same period (Statistics South Africa. 2009b). The African population in the 
Free State, like the rest of South Africa, has the largest unemployment rate, at 30.8%, 
which is slightly higher than the countries national unemployment rate (Jacobs, Punt 
2009). The Free State is not considered to be the poorest province. The districts lie 
within the third and fifth socio economic quintile (1=poor; 5=rich). Thabo 
Mofutsanyane district lies in the third quintile and has the highest deprivation index of 
2.92 (Health Systems Trust. 2008). The levels of inequalities between the rich and poor 
are high as in the rest of South Africa (0.75) (Jacobs, Punt 2009). The Gini coefficient is 
an indicator used to show the income inequalities, and ranges from 0 or perfect equality 
to 1 or complete inequality (World Bank. 2009). In the province this value is 0.66 and is 
highest within the African population 0.60 (Jacobs, Punt 2009). 
Most households (97.3%) in the province have access to safe drinking piped water, 
either inside the dwelling or outside in a communal area. Almost 20% of the households 
in the Free State are informal settlements, higher than the national average of 14.4% and 
the province is ranked third highest. 61.4% of the households have flush toilets, 22.6% 
use pit latrines (7.9 with ventilation, 14.7 without ventilation), 12.7% use the bucket 












households still using the bucket system as compared to the national average (2.2%) 
(Statistics South Africa. 2007a) . 
Health Service Provision 
Within the province four health complexes are responsible for providing public sector 
health services. These health complexes are compromised of 24 district hospitals, 5 
regional hospitals, 1 tertiary and 1 psychiatric hospital. There are 258 fixed clinics, 121 
mobile clinics 14 community centres responsible for primary health care (Table 1).   
Table 1 Free State health facility distribution 





Population  133 668 790 955 758 097 767 862 518 024 2 968 604 
District Hosp 4 4 5 8 4 25 
Regional Hosp 0 1 1 2 1 5 
Tertiary Hosp 0 1 0 0 0 1 
Central Hosp 0 1 0 0 0 1 
Specialist Hosp 0 3 0 0 0 3 
Fixed Clinics 17 69 45 67 33 231 
Mobile Clinics 21 20 25 21 25 112 
*CHCs 1 5 1 1 27 35 
Total Clinics 38 93 71 89 59 350 
Table adapted from Health Systems Trust 2007/2008 * Community Health Center 
In the province, 15.8% of the population have health insurance and 84.2% depend on the 
public sector. Motheo district has the highest medical aid coverage (24.7%), while 
Thabo Mofutsanyane (5.3%) and Xhariep (8.4%) have less than 10%. The nurse clinic 
work load in Free State is 36.9 patients per nurse per day, and is higher than the 23.7 
patients per nurse per day in South Africa. Fezile Dabi, Lejweleputswa and Thabo 
Mofutsanyane have patient workloads over 40.0 patients per nurse per day, while 
Motheo has the lowest nurse work load of 28.9 patients per nurse per day. The 
utilisation rate of primary health services in the province is 2.0 visits per person per year 
and is similar to the national average of 2.2 visits per person per year. This rate is below 
the Department of Health target of 3.5 visits per person per year. Lejweleputswa has the 













Most women attending antenatal services in the province are tested for HIV (80.1%). In 
2007 over 90% of the pregnant women in Fezile Dabi, and Xhariep were tested, whilst it 
was lowest in Lejweleputswa (74.7) and Motheo (75.6). Most women (84.8%) deliver in 
heath facilities, higher than the national average of 80.6%. Xhariep has the lowest 
percentage (57.9%) while over 90% of women in Lejweleputswa and Motheo deliver in 
health facilities. 11.8% of pregnant women deliver via caesarean section, this is lower 
than the national average (15.6%), and Fezile Dabi (16.6%) and Motheo (17.3%) have 
higher percentages compared to Lejweleputswa (9.6%) and Thabo Mofutsanyane (9.7%) 
(Table 2). 
 
Table 2 Provincial health indicators 
 Fezile Dabi Lejweleputswa Motheo Thabo 
Mofutsanyane 
Xhariep Free State National 




18.9% 14.6 24.7 5.3% 8.4% 15.8% 14.3 
Access to piped 
water 
97.1% 97.4 98.8 96.4% 92.5% 97.3% 85.8% 
Deprivation 
Index * 
1.59 2.04 2.12 2.92 2.27 - - 
Social Economic 
quintile ** 
5 4 3 3 3 - - 
Nurse clinical 
workload 
44.2 40.5 28.9 40.3 35.9 36.9 23.7 
Caesarean section 
rate 
16.6% 9.6% 17.3% 9.7% 0.0 11.8% 15.6% 
Proportion ANC 
clients tested for 
HIV 




33.0% 37.0% 27.4% 30.7% 28.3% 33.6% 28.3% 
Utilisation rate 2.0 1.6 1.9 2.4 2.8 2.0 2.2 
 
Diarrhoea 
incidence under 5 
170.2 171.7 161.4 158.7 260.1 168.9 254.0 
Percentage of  
woman delivering 
in public facilities 
78.7% 91.7% 92.4% 80.5% 57.9 84.8% 80.6% 
Table adapted from the Health Systems Trust Health Barometer 2007/008 * High value most deprived ** 













HIV/AIDS Disease Burden in the Free State 
In 1991 HIV prevalence amongst pregnant women attending antenatal services in the 
public sector in the Free State was 1.5% and by 1996 this increased to 17.5% (DOH. 
2009b, DOH 2009c). Since 2001 there has been no statistically significant increase in 
HIV prevalence (DOH. 2009b, DOH 2009c). In 2001 the prevalence was 30.1% and 
33.5% in 2007 (DOH. 2009b, DOH 2009c). In 2007 Lejweleputswa (37.0%) had the 
highest prevalence while Xhariep (24.0%) had the lowest (Table 3).   
 
Table 3 HIV prevalence among antenatal attendees in the Free State 2007 
 Prevalence % 95% Confidence Interval 
Free State  33.5 28.3-39.1 
Fezile Dabi 33.0 28.2-38.1 
Lejweleputswa 37.0 33.1-41.1 
Motheo 27.4 23.8–31.3 
Thabo Mofutsanyane 30.7 26.9-34.8 
Xhariep 24.0 16.7–32.6 
Table adapted from the National HIV and Prevalence Survey 2008 
 
In 2006 the ASSA model estimated that HIV/AIDS accounted for almost 51% of deaths 
(Dorrington et al. 2006). In 2006 it was estimated that 3.6% of infants were infected 
perinatally while a further 2.5% were infected through breast milk in the province 
(Dorrington et al. 2006). Provincially infant and child mortality rates have declined 
since the peak in 2001. In 2001 the infant mortality rate was 72/1000 live births and the 
under five mortality was 106/1000 (Dorrington et al. 2006). By 2006 the infant mortality 
rate decreased to 57/1000 live births and the under five mortality to 87/1000 (Dorrington 
et al. 2006). The decrease in mortality may be related to an increase in the number of 
women accessing PMTCT in the province. In 2006/2007 it was estimated that about 
60% of HIV infected mothers and their exposed infants received prophylaxis in the 















Definition of Terms and Measurements for Surveillance 
Population NVP Coverage: the proportion of HIV-exposed infants in the population in 
whom both maternal and infant doses were ingested (Stringer et al. 2005). Infant HIV 
exposure was determined by cord blood testing, maternal nevirapine ingestion by the 
presence of nevirapine in the cord blood and infant nevirapine ingestion from the 
clinical records at the delivery facility.  
 
Calculation of maternal adherence: the number of women in whom nevirapine was 
detected in the cord blood divided by the total number of HIV infected women who 
were dispensed with the intervention.   
 
Study Design 
This study used a cross-sectional design.  
 
Study Population and Sampling 
The study population included women who delivered within three randomly selected 
sub-districts in the Free State. These women attended maternity sites in one 
metropolitan area (Botshabelo) and in four small towns (Ladybrand, Ficksburg, 
Clocolan and Senekal) in Motheo and Thabo Mofutsanyane districts. From Thabo 
Mofutsanyane district, Itemoheng District Hospital in Senekal, JD Newbury District 
Hospital in Clocolan and Phutuhola District Hospital in Ficksburg were selected. From 
Motheo district, Mantsopa district hospital in Ladybrand and Botshabelo district hospital 














From November 2007 to April 2008 cord blood specimens were collected from all live 
deliveries. Infants born before arrival at the maternity site and those still born were 
excluded from the study. 
 
Sample Size 
The required sample size was calculated using the EPICALC 2000 software. Sample 
size estimates were based on 50% PMTCT coverage, (based on earlier unpublished 
studies), and a margin of error around the estimate of 5% (i.e. 95% confidence interval 
between 0.45 and 0.55). The sample size required was 384 HIV-infected specimens. As 
the average prevalence in the areas where the study was conducted was 30%, an overall 
sample size of 1078 was required. The sample size for each site was based on the HIV 
prevalence at that site. The study was commenced at each site and continued until over 
95% of specimens from the required sample size was collected.  
 
Measurement  
After delivery cord blood specimens from discarded placentas were collected by the 
health care worker performing the delivery. Five cm3 of blood was collected and placed 
in an anticoagulated (EDTA) tube and assigned a number. In instances where multiple 
births were recorded, only one cord blood specimen was obtained. Information was 
collected from the mother‟s chart relating to the pregnancy. No patient identifiers were 
included. The blood specimens were sent to a central location where a rapid assay for 
HIV antibodies was conducted, in an effort to preserve anonymity. For every positive 
result, a small amount of blood was placed on a filter paper, placed in a plastic bag and 
refrigerated. These specimens were tested for nevirapine using chromatography at the 














This following information was collected from the mother‟s clinical chart: the mother‟s 
age, gravidity, the month and year of delivery, the delivery site, the mode of delivery, if 
the mother was offered pre-test counselling, if she accepted HIV testing, if the results of 
the test were given back to the mother, if ART was dispensed to the mother, whether the 
infant was administered prophylaxis and if formula milk was given on discharge. This 
information was collected by nurses. All forms were checked by study staff for quality 
assurance to see if information was complete. In instances where women delivered at 
sites different to where they attended antenatal care, information was retrieved from the 
health passport or otherwise recorded as unknown. 
Validity and Reliability 
The cord blood specimens were tested for HIV antibodies with a rapid test algorithm 
(Determine HIV 1/2 test, Abbott Laboratories, Chicago, Illinois). In the case of 
discrepancies, a second Determine test was done. A second Determine test was 
conducted by a different person on 10% of specimens for quality control. The Determine 
test kit has a sensitivity of close to 100% (95% CI 99.8-100.0%) and specificity of 
99.9% (95% CI 99.8-99.4%) (Wright, Stringer 2004). 
High performance liquid chromatography was used to detect nevirapine. Nevirapine was 
extracted from the dried blood spots (DBS) with 80% methanol, 20% 0.2M zinc 
sulphate containing neostigmine as internal standard. The chromatography analysis was 
carried out on the Phenomonex Fusion RP column (5x2x4um) using a methanol/10 mM 
ammonium acetate gradient to effect elution. Detection was achieved using an Applied 
Biosystems API 3200 tandem mass spectrometer in the MRM detection mode. Detection 
of nevirapine in dried blood spots (DBS) was carried out by a validated method using 












For qualitative assessment blank and quality control cut off samples were included with 
each run. The limit of detection for nevirapine was set at 0.1μg/ml. Values detected 
above this limit were reflected as positive and those below as negative. For quantitative 
assessment standard curves were run in the range 0.1– 10μg/ml and appropriate quality 
control samples run with each batch. The limit of quantification was 0.1 µg/ml.   
Data Management and Analysis 
Data was collected, checked and double entered at a central location by trained data 
capturers. The data was entered into an encrypted MS Access database for security. For 
quality assurance purposes, data entry errors were identified by comparing every 10th 
entry into the database. 
Data was exported from MS-Access to STATA version 10 for analysis. T- tests were 
used to compare continuous variables between different groups and Chi squared tests for 
categorical variables. Both univariate and multivariate logistic analysis were used to 
determine the factors associated with maternal and infant adherence. Results were 
analysed as prevalence odds ratios with their corresponding p-values and confidence 
intervals. 
Ethical Considerations 
Ethics approval was granted by the University of Cape-Town Ethics Committee 
(approval number REC REF 038/2007), the Centre for Disease Control (CDC) and the 
University of Alabama. 
Confidentiality and anonymity were assured as there were no identifiers on cord blood 













the women in the study. Confidentiality was maintained as only the study personnel had 
access to the database which was securely protected by a password. Women were 
informed of the study through talks given by service providers at the antenatal care 
services.  
Individual informed consent was not obtained from mothers for the following reasons: 
 There was no risk to the patient as blood was taken from the discarded placenta. 
 The rights of the patient were not harmed. Patients still had access to the 
facilities and the usual care that the facilities provided. Anonymity was assured 
since HIV assay results could not be linked to a woman.  
 Obtaining informed consent from women participating would have led to 
selection bias. A study in Lusaka showed that women who refused testing were 
more likely to be HIV infected. (Stringer et al. 2005) . 
The study had no direct benefits for the participants. Information gathered by this study 





































During the surveillance period 1679 women delivered in facilities in the Free State and 
1650 (98.27%) specimens were collected and tested for maternal HIV antibodies. 
Specimens were not collected from 11 women (0.66%) and 18 (1.07%) of those 
collected were not tested1. Mothers in whom specimens were not collected or tested had 
a shorter median interval between the last antenatal visit and delivery; their infants also 
had a lower median birth weight as compared to those in whom specimens were 
obtained and tested. The gravidity, the number of antenatal visits and the age of the 
mother did not differ between mothers in whom a specimen was collected or tested and 
those in whom specimens were not collected or tested (Table 4). A further 31 HIV 
positive women were excluded from the analysis because their babies died or were 
stillborn (n=8) and because no nevirapine cord result was obtained (n=23). The 
remaining 1619 (96.4%) women therefore make up the surveillance population of which 
29.2% were HIV positive (Figure 3).  
Table 4 Characteristics of mothers in whom cord blood testing was performed compared 
to those in whom no test or specimen was obtained 
Variable No specimen Result 
n=29 
Specimen Results Obtained 
n=1650 
P-value 
Median Infant Birth weight (g) 2700 [IQR 1900-3100] 3017.5 [IQR 2780-3300] 0.001 
Median Mothers Age (years) 26 [IQR 22-30] 24 [IQR20-29] 0.322 
Median Gravidity 2 [IQR 1-3] 2 [IQR 1-3] 0.496 
Interval in months between last 
ANC visit and delivery 
1 [IQR 0-1] 0 [IQR 0-1] 0.012 
Interval between testing and 
delivery (in months) 
3 [IQR 2-4] 3 [IQR 2-4] 0.329 
Mode of Delivery 
 
   







    Caesarean 6.9% (n=2) 9.7% (n=159)  
  
                                                          
1 11 Specimens not collected (1 born before arrival, 1 cord snapped, 2 forgot to take sample, 1 fresh 
stillbirth, 4 macerated stillbirth, 1 Other-Unspecified, 1 resuscitating patient) 












Figure 3 Free State cord blood study profile 
1679 Women Gave birth to  Infants 
11 specimens not collected
1668 Specimens Collected 
 18 not tested
1650 Specimens Tested, 499 (30.2%) Positive on Cord blood 
10 babies died/still births from positive women 
21 no NVP results from HIV positive women 











Characteristics of Surveillance Population 
Almost 80% of the women that made up the surveillance population were from the 
Hospital facilities (Botshabelo Hospital, Phuthuloha Hospital, Mantsopa Hospital, JD 
Newbury Hospital, Itemoheng Hospital and Dr Pedro Hospital) the remaining 20% were 
from the clinic facilities (Winnie Mandela, Pule Sefatsa, Maletsatse Mabaso, 
Itumelang). 
The median age of mothers was 24 years [IQR 20-29yrs]. The median number of 
pregnancies was 2 [IQR 1-3]. Mothers had a median of 4 [IQR 3-6] antenatal visits. 
93.8% of the mothers who delivered in the facilities attended at least one antenatal visit. 
There was no significant difference in number of antenatal visits, the mode of delivery, 
the interval in months between testing and delivery and the interval between the last 
antenatal visit and delivery between HIV-infected and HIV-negative women. The 
median age for HIV-infected women was 27 years and 23 years for HIV-negative 
women. A minority of the mothers 10.2% reported that they had previously been tested 
for HIV. All women who reported that they were HIV-infected were positive on cord 
blood HIV antibody testing. Twenty three point five percent of women who reported 
that they were negative were found to be positive on cord blood testing. The majority of 
the mothers (90.5%) delivered vaginally and 9.5% delivered via caesarean section 




















    






Median Mothers Age (years) 24 [IQR 20-29] 27 [IQR 24-31] 23 [IQR 20-28] 
Median Gravidity 
 
2 [IQR 1-3] 
 
2 [IQR 2-3] 
 
2 [IQR 1-3] 
 
Median Interval between testing and 
delivery (months) 
3 [IQR 2-4] 3 [IQR 2-4] 3 [IQR 2-4] 
Median number of antenatal visits 4 [IQR 3-6] 4 [IQR 3-6] 4 [IQR 3-6] 
Mode of Delivery 
    Caesarean  










Previous HIV test done 
    Yes 










Previous Positive result 
Previous Negative result 








HIV Prevalence of Women Delivering in Facilities in the Free State 
The overall HIV prevalence in the surveillance population was 29.2% (n=472) (95% CI 
26.9-31.4%). HIV prevalence did not differ significantly between facilities p=0.795 
(Table 6). Mothers aged less than 19 years and those aged 20-24 years had the lowest 
HIV prevalence 9.8% (95% CI 6.7-13.7%) and 23.5% (95% CI 19.9-27.3%) 
respectively. Mothers aged 25-29 years and those aged 30-34 years had the highest HIV 
prevalence of 42.2% (95% CI 37.3-47.1%) and 41.6% (95% CI 35.1-48.3%) 













Mothers who had not received pre-test counselling had a lower prevalence than those 
who received pre-test counselling (23.0% n=52, 30.2% n=392) p=0.028. Similarly 
mothers who refused testing had a lower prevalence as compared to those who accepted 
testing (22.7% vs. 31.5%) p=0.016 (Figure 5). These results are based on the cord blood 
analysis results. 
Table 6 HIV prevalence of mothers delivering in public facilities in the Free State 
 Facility HIV Prevalence 95% Confidence Interval 
Botshabelo Hospital 29.2%   (72/247) 23.6-35.2 
Dr. Pedro Hospital 34.5%   (20/58) 22.4-48.1 
Itemoheng Hospital 29.1%   (70/241) 23.4-35.2 
Itumelang M Clinic 31.3%   (21/67) 20.5-43.8 
JD Newbury Hospital 24.5%   (52/212) 18.9-30.8 
Maletsatse Mabaso B Clinic 24.1%   (21/87) 15.6-34.5 
Mantsopa Hospital 31.7%   (109/344) 26.8-36.9 
Phuthuloha Hospital 30.1%   (64/213) 24.0-36.7 
Pule Sefatsa U Clinic 27.8%   (20/72) 17.8-39.6 
Winnie Mandela J Clinic 29.5%   (23/78) 19.6-40.8 
Total 29.2%   (472/1619) 26.9-31.4 
Age Category 
Less than 19 9.8%    (30/305) 6.7-13.7 
20-24 23.5%   (122/519) 19.9-27.3 
25-29 42.2%   (172/408) 37.3-47.1 
30-34 41.6%   (94/226) 35.1-48.3 
35+ 33.5%   (54/161) 26.3-41.4 
Free State Population PMTCT/Coverage Cascade 
The PMTCT cascade describes the events that need to be followed for the intervention 
to be delivered and allows for coverage to be estimated. Coverage refers to maternal 
(nevirapine present in cord blood) and infant ingestion (documented in records) of the 
prophylaxis. Of the 1619 mothers in the surveillance population 94.1% (n=1523) had 
complete information in the clinical folder of whether they had been offered or accepted 
testing during antenatal care (Cascade Step1 Figure 4 & Figure 5). Of the mothers who 












Step2 Figure 4 & Figure 5). However 28.7% (n=65) of all the mothers who did not 
receive pre-test counselling according to the clinical records had not attended antenatal 
care. Of the mothers that were pre-test counselled, 85.7% agreed to testing (n=1112) 
(Cascade Step3 Figure 4 & Figure 5). All mothers who tested received either a positive 
or negative test result. 790 (71.0%) mothers received a negative test result and 322 
(29.0%) received a positive result (Cascade Step4 Figure 4 & Figure 5.). Of those that 
received a negative test result during antenatal care, 752 were also negative on cord 
blood testing at delivery but 38 tested positive on cord blood antibody. Of the 322 
women that received a positive test result during antenatal care, 312 were also found to 
be positive on cord blood testing, and 10 women who were given a positive test result 
during antenatal care were found to be negative on cord blood testing (Table 7). 
Table 7 Comparison of HIV test results received during antenatal care and results 
obtained during cord blood testing. 
 Cord blood  Testing 
Antenatal Care Test Result Positive Negative Total 
Positive 312 10 322 
Negative 38 752 790 
Total 350 762 1112 
312 mothers were identified as HIV-infected on cord blood testing (Cascade Step5 Fig.2 
& Fig.3). According to the clinical records 93.7% (n=291) of HIV-infected women on 
cord blood testing were dispensed with PMTCT, the remaining 6.9% (n=21) did not 
receive any intervention. Of these women who received the intervention, 245 (Cascade 
Step6 Figure 4 & Figure 5) had nevirapine detected in the cord blood. Thus maternal 
adherence was 84.2%. 88.2% (n=216) of infants born to mothers who were adherent to 
the intrapartum nevirapine, received the required dose directly observed. All infants 
received the nevirapine dose within 72 hours of birth. 29 infants did not receive their 













50.4%), and thus 256 (54.2%) of the 472 HIV exposed live infants missed the 
opportunity to receive both the maternal and infant PMTCT doses. Of the infants who 
received both maternal and infant doses 46.7% were discharged with replacement 
feeding and only 11.8% of those infants who failed to receive the recommended 
prophylaxis. 
 
Figure 4 PMTCT attrition cascade among surveillance population across 10 delivery sites 
in the Free State 
 
Figure 5 shows the sequence of events that had to be followed in order to achieve successful PMTCT coverage Step 0 
(leftmost bar) represents all women in the surveillance population who stratified by cord blood HIV status at delivery. 
Coverage defined as the proportion of infected/exposed mother/infant pairs that received maternal and infant 
nevirapine doses was 45.8% (216/472). * There were 28 HIV infected/exposed cases who failed coverage (i.e. no 


















Figure 5 Flow diagram showing attrition from the PMTCT program in the Free State 
0)1619  Documented deliveries 29.2% (472 positive 1147 negative)
296 Missing Information on chart 
29.2% (68 Negative, 28 Positive) 
1) 1523 Complete Information in chart 29.2% (444 Positive, 1079
Negative) 
226 No Pre-test counselling received 
 23.0% (52 Positive, 174Negative) 
2)1297 Received pre-test counselling (392 Positive, 905 Negative)  30.2%
185 refused testing 22.7% 
(42 positive, 143 negative) 
3)1112 were  tested (350 Positive, 762 Negative) 31.5%3
4) 322 Received Positive Result (312 Positive, 10 Negative)
23 did not receive the intervention 
(21 Positive, 2negative) 
5) 299 Mothers dispensed with the intervention (291 Positive, 8negative)
 54 no nevirapine detected 
(46 Positive 8 negative) 
6) 245 Nevirapine detected in the blood
29 infants did not receive maternal dosing 
7) 216 Maternal and Infant dosing
2
  The 96 women who had missing chart information and those who did not for HIV testing-HIV results 
are based on the cord blood results. 












Determining the factors related to maternal adherence 
In a univariate logistic analysis, maternal adherence was not associated with the infants‟ 
birth weight, gravidity, the mothers age, the mode of delivery, the type of intervention 
received nor the interval between the last ANC visit and the interval between testing and 
delivery (Table 9). In a multivariate analysis, after adjusting for the mothers age and the 
type of intervention received, mothers who had attended more than 5 antenatal visits 
were 2.76 times more likely to be adherent than mothers who attended less than 4 visits 
(p=0.030). However there was no significant difference between mothers who attended 
4 or 5 visits and those who attended 3 or less (p=0.645). The mothers‟ age and the type 
of intervention received were not significantly associated with adherence after adjusting 
for the other variables (Table 10). 
Table 8 Characteristics of HIV-infected mothers in the Free State by adherence status 




Median baby Birth weight(grams) 3000 IQR [2700-3300] 3016 IQR [2670-3400] 
Median Mother age (years) 27 IQR[24-31] 27 IQR[25-30] 
Gravidity 
     1 20.8% 
 
26.7% 
 2-3 63.7% 
 
60.0% 
 4+ 15.5% 13.3% 
Interval Between Testing and delivery 
0-3 months 55.5% 56.5% 
4 months or more 44.5% 43.5% 
Interval between last ANC visit and delivery 
   
> 
      Less than 1 month 57.6% 
 
54.4% 
     1 month or more 42.5% 45.7% 
Number of Antenatal Visits 
       3 or less 30.6% 
 
37.0% 
 4-5 34.7% 43.5% 
 6 or more 34.7% ( 19.6% 
Mode of Delivery 
     Vaginal 89.8% 91.3% 
    Caesarean 10.2% 8.7%  
Type of Intervention Mother  received 
      NVP only 90.0% 
 
95.7% 
















Table 9 Univariate regression analysis for determining factors for maternal adherence in 
the Free State 
Variable Odds Ratio 95% CI P Value 
Birth weight 1.00 0.99-1.00 0.752 
Gravidity 
1    1 1.00 - - 
2-3 1.47 0.71-3.07 0.301 
    4+ 1.61 0.56-4.63 0.373 
Mothers Age 1.01 0.96-1.08 0.633 
 No. of ANC Visits 
    3 or less 1.00 - - 
4-5 0.96 0.47-1.97 0.919 
    6 or more 2.14 0.90-5.09 0.085 
Mode of Delivery 





     Vaginal 0.84 0.27-2.53 0.754 
Type of intervention 
- -
    HAART/AZT+NVP 1 
    NVP only 
 
0.63 0.30-1.34 0.237 
Interval between last ANC visit and delivery 





     1 month or more 0.89 0.46-1.65 0.687 
Interval between testing and delivery 
0-3months 1 - - 
4 months or more 1.04 0.52-1.97 0.889 
Table 10 Multivariate regression analysis for determining factors related to maternal 
adherence in the Free State 
Variable Adjusted Odds 
Ratio 
95% CI P Value 
Mothers age 1.01 0.95-1.09 0.586 
Type of Intervention Offered 
    AZT+NVP/HAART 1.00 - - 
    NVP only 0.67 0.31-1.41 0.289 
No. of ANC visits 
1-3 1.00 - - 
4-5 1.19 0.57-2.50 0.645 












Reasons for failed coverage 
 Of the 472 live infants born to HIV positive mothers in whom cord blood testing was 
performed, only 45.8% (95% CI 41.2-50.4%) had evidence that they received both the 
maternal and infant doses of ARV prophylaxis. Reasons for failed dosing included, not 
offered pre-test counselling, refused testing, did not receive a positive test result 
prophylaxis was not issued, the mother did not adhere and the infant did not receive the 
prophylaxis dose. 
Figure 6 Population PMTCT coverage and reasons for failed coverage 
Factors associated with successful PMTCT coverage 
In the multivariate regression HIV-infected mothers who attended 4 or 5 antenatal visits 
were 2.16 times more likely to have their infants successfully received the appropriate 
prophylaxis than those who attended less than 3 (p=0.001). Similarly HIV-infected 
mothers who attended 6 or more visits were 2.71 times more likely to have their infants  
receive the full prophylaxis as compared to those who attended 3 or less visits 












Table 11 Characteristics of HIV-infected and exposed infants in the Free State by coverage 
Variable Successful Coverage 
N=216 
Failed Coverage N=256 
Median Mothers age (years) 26  IQR[24-30] 27 IQR[24-32] 
Gravidity 
    1 20.8% 27.5% 
2-3 62.5% 60.4% 
4+ 16.7% 12.2% 
Interval Between Last ANC visit and delivery 
    Less than 1 months 57.9% 49.6% 
    1 month or more 42.1% 50.4% 
Number of Antenatal Visits 
    3 or less 28.2% 45.2% 
4-5 37.1% 31.2% 
6 or more 34.7% 23.6% 
Median Birth weight (grams) 3000 IQR[2715-3300] 3000 IQR[2600-3290] 
Mode of delivery 
    Caesarean 11.1% 8.2% 
    Vaginal 88.9% 91.8% 
Having had more pregnancies was significantly associated with successful coverage. 
HIV-infected mothers who had four or more children were more likely to have their 
infants receive both the infant and maternal doses as compared to those who only had 
one child (p=0.011). However this association was not significant in having had 2 or 3 
children as compared to having had only 1 child. There was no significant association 
between successful coverage and the birth weight of the infant (Table 13). In the 
univariate regression, an increase in mothers‟ age was significantly positively associated 
with successful coverage, however during the model building process this effect 












Table 12Univariate regression analysis for factors related to successful PMTCT coverage 
Variable Odds Ratio P-value 95% CI 
Birth weight 1.09 0.007 1.04-1.11 
Gravidity 
    1 1.00 - 
2-3 1.38 0.179 0.89-2.15 
    4+ 1.83 0.051 0.99-3.37 
No. of ANC visits 
    <3 1.00 - - 
4-5 2.13 0.001 1.37-3.31 
    6+ 2.64 <0.001 1.67-4.19 
Mothers age 1.04 0.038 1.00-1.07 
Mode of Delivery 
    Caesarean Section 1.00 - - 
    Vaginal Delivery 0.71 0.286 0.39-1.32 
   Interval between last ANC visit and delivery 
    Less than 1 month 1.00 - - 
    1 month or more 0.72 0.073 0.50-1.03 
CI, Confidence Interval 
Table 13 Multivariate analysis for factors associated with successful PMTCT coverage 
Variable Adjusted Odds Ratio P-value 95% CI 
Birth weight 1.00 0.137 0.99-1.00 
No. of ANC visits 
    <3 1 - 
<0.001
- 
4-5 2.16 0.001 1.37-3.42 
6+ 2.71 <0.001 1.66-3.70 
Gravidity 
    1 1.00 - - 
2-3 1.42 0.30 0.90-2.24 
    4+ 2.30 0.011 1.21-4.37 














Despite the wide-spread availability of PMTCT services in the Free State, less than half 
of the infants born to HIV-infected mothers received appropriate prophylaxis. The study 
showed that attrition occurred at all stages of the cascade resulting in reduced coverage. 
Studies conducted in Africa have shown that coverage was poor (Manzi et al. 2005, 
Perez et al. 2004, Temmerman et al. 2003, Stringer et al. 2005). In Kenya 20% of 
mother infant pairs received the appropriate prophylaxis (Temmerman et al. 2003) and 
30% in Zambia (Stringer et al. 2005). 
Studies in routine PMTCT services in Africa have reported low uptake of VCT services 
among antenatal attendees (Ekouevi et al. 2004, Pignatelli et al. 2006, Meda et al. 2002). 
In this study more than 80% of women were tested and this was encouraging. The use of 
rapid tests, the availability of same day results and confidential „one-on-one‟ counseling 
sessions with well trained staff may have been associated with higher uptake of VCT. 
Other studies conducted in South Africa (Coetzee et al. 2005, Jackson et al. 2007) have 
also noted high uptake of VCT. However about 20% of HIV-infected women in this 
study failed to enroll into the program because they were not offered or refused testing 
and this has important implications for the success of PMTCT programs. Similar 
proportions of women were either not offered or refused testing. VCT services therefore 
need to be strengthened and all women should be offered an HIV test and need to be 
encouraged to test.  
Counsellors and health care workers need to be motivated and encouraged to provide women 
with high quality counselling. In Zimbabwe in service training sessions and validated teaching 
tools such as flip charts were developed to strengthen interview skills and provide 












(Chandisarewa et al. 2007). Monitoring was introduced to ensure adherence to PMTCT 
protocols and staff competency was assessed (Chandisarewa et al. 2007). Community 
engagement through effective communication strategies that improve HIV/AIDS 
awareness including primary prevention of HIV and PMTCT need to be strengthened. 
Women in particular need to be empowered on their reproductive rights and encouraged 
to practise safer sex. Efforts also need to be established to reduce discrimination and 
stigma towards people living and affected by HIV/AIDS. 
In this study the majority of women who delivered in the facilities (94%) attended at least one 
antenatal visit. This finding is consistent with reports from other parts in Africa (Moses et 
al. 2008). However 6% of HIV-infected women failed to receive prophylaxis because 
they had not attended antenatal services according to clinical records. Offering HIV 
testing in the labour ward is a strategy that can be adopted for mothers who did not 
attend antenatal care but deliver in facilities (Temmerman et al. 2003, Homsy et al. 
2006). This also gives women who are not offered or those who refuse testing another 
opportunity to know their HIV status and participate in the program. These mothers and 
their infants will then have access to intrapartum and postpartum prophylaxis. 
Implementation of labour ward testing has been found to be acceptable and feasible (Pai 
et al. 2008). In India 98% of women offered testing were tested in the labour ward (Pai 
et al. 2008). In Uganda, 88% of women who presented in the labour ward with 
undocumented HIV status were tested during delivery (Homsy et al. 2006). Health care 
workers should also be encouraged to ask HIV infected mothers whether they were 
given or remembered to take their prophylaxis when they present in labour, and in 
instances where prophylaxis this was not taken they should be administered.  
In addition to the 6% of HIV-infected women in this study who did not attend antenatal 
services, a further 5% of HIV-infected women had no record of whether they had been 
offered VCT services or if they had refused testing. Nevirapine was not detected in the 











keeping should be emphasised. Staff and health care workers should be well-trained on 
record keeping and capture data for monitoring and evaluation purposes. Simple, 
effective and preferably electronic record keeping systems that link patient data should 
be developed for each facility (Reithinger et al. 2007). Centralised databases that allow 
for the access to patient information from any facility within the province will help 
reduce attrition from the program in the event that women are referred or transferred to a 
different facility for delivery or antenatal care.   
The overall HIV prevalence in the surveillance population was 29.2%. This is consistent 
with the Free States Provincial antenatal prevalence at that time (DOH. 2009). Contrary 
to a study in Lusaka, Zambia (Stringer et al. 2005), women who were not offered pre-
test counselling and those who refused testing, had a lower HIV prevalence than those 
who were tested during VCT. This may be explained by the fact that women who 
perceive themselves to be at risk of infection are more likely to accept testing (Mpairwe 
et al. 2005). This finding is consistent with findings reported in Uganda where women 
who were tested in pregnancy had a higher HIV prevalence than those who refused 
testing but were anonymously tested (Mpairwe et al. 2005).   
This surveillance showed that 8% of HIV-infected mothers at delivery were 
seronegative when tested at their first antenatal visit. This finding is similar to the 6% 
reported in Zambia (Stringer et al. 2005). It is also consistent with findings reported in 
KwaZulu-Natal, where 7% of women in the study had a negative HIV test result during 
pregnancy, but were found to have HIV-infected infants when their infants were tested 
postnatally (Rollins et al. 2007a). These women either seroconverted during pregnancy 
or were false negatives when they tested at their first antenatal visit or testing 
information was incorrectly recorded at the antenatal facilities. Women may seroconvert 












2009). A South African study recommended repeat testing late in pregnancy (Moodley 
et al. 2009) .  
HIV-infected women in the Free State were given the nevirapine at 28 weeks of 
gestation. In this study 93% of mothers who were identified as HIV-infected during 
pregnancy were dispensed with the intervention. In a study in Lusaka less than 1% of 
HIV positive women either failed to receive the intervention or did not collect the test 
results. In a study in the Eastern Cape over 40% of pregnant women who were identified 
as HIV-infected failed to receive nevirapine (Peltzer et al. 2008). Women may not return 
and collect their prophylaxis because of fear and stigma. In Kenya women are now 
given the prophylaxis during post-test counselling irrespective of their gestational stage 
(Temmerman et al. 2003). 
A strength of this study was the ability to objectively determine the rate of maternal 
adherence. Unlike other studies that have relied on pill counts or self reports to measure 
maternal adherence (Albrecht et al. 2006, Bii et al. 2007, Kiarie et al. 2003), cord blood 
specimens were used to detect whether nevirapine had been taken. In this study almost 
20% of women who were given the intervention according to the clinical records had no 
nevirapine detected in the cord blood. This finding is lower than the 32% non adherence 
rate reported in the study in Lusaka, Zambia which used similar methods to measure 
adherence. Identified HIV-infected women in the Free State were given nevirapine to 
take once they went into labour. This surveillance showed that women who attended 
more antenatal visits were more likely to have nevirapine in their cord blood. This 
association is consistent with the findings reported in Kenya (Bii et al. 2007). This 
suggests that there are more opportunities for health care workers to encourage, support, 
and re-emphasise the importance and benefits of adhering to therapy if they attend more 












In this study 6% of infants born to seropositive mothers who had nevirapine in their cord 
blood, did not receive their nevirapine dosing. All the infants who received their dosing 
received it within 72 hours of delivery in the facility by the health care worker. Other 
studies report that nevirapine syrup is provided in blister packets for self administration 
for women delivering at home and this has resulted in infant adherence of almost 90% 
(Peltzer et al. 2008). In this study HIV-infected women who attended more antenatal 
visits were more likely to have their infants receive both maternal and infant doses. A 
woman who refused or was not offered HIV testing on her first antenatal visit may 
accept testing or be offered testing at subsequent visits. This finding was similar to a 
study conducted in KwaZulu-Natal where women who attended less antenatal visits 
were at increased risk of transmission (Rollins et al. 2007). The WHO has recommended 
that pregnant women in resource constrained settings should attend that at least four 
antenatal care visits to achieve positive maternal health outcomes (Villa et al. 2001). An 
increase in gravidity was positively associated with successful coverage. This finding 
may suggest that mothers who have more children may comprehend and understand the 
need to follow all the steps in the cascade as they are likely to be more experienced in 
mother hood as compared to new mothers. Furthermore these mothers may have been 
informed of PMTCT during earlier pregnancies at ANC sites through communication 
strategies and thus managed to successfully complete all the steps in the cascade. 
Study limitations 
This study had a number of limitations. The study excluded women who did not deliver 
in public sector antenatal facilities. In the Free State province it was estimated that 15% 
of women did not deliver in health care facilities (Health Systems Trust 2008). This 
study therefore missed women who delivered at home. In KwaZulu-Natal, it was found 
that home deliveries were associated with an increased risk of transmission (Rollins et 
al. 2007a); therefore the coverage estimate in this study may be over-estimated. Home 
deliveries are common in other parts of Africa (Manzi et al. 2005, Moses et al. 2008, Bii 












Another weakness of this study was that it was insufficiently powered to detect factors 
related to maternal adherence. Other studies have found that disclosure of status to the 
partner, education level, maternal age and mode of delivery were associated with 
maternal adherence (Peltzer et al. 2008, Albrecht et al. 2006, Bii et al. 2007, Kiarie et al. 
2003). This study also relied on the medical records to determine if the infant received 
the nevirapine however if the infant was dosed and this not documented then the infant 
was incorrectly classified as non-adherent thereby underestimating the coverage.  
Finally, the main outcome measure in this study was coverage, but this only serves as a 
proxy to measure effectiveness (Stringer et al. 2008). The HIV free survival has been 
proposed to be the most important metric for estimating effectiveness in high prevalence 
and resource limited settings (Stringer et al. 2008). Because this was a cross-sectional 
study and HIV-exposed infants were not followed up and tested to determine HIV 
infection the HIV free survival could not be estimated. This study was able to point out 













CONCLUSION AND RECOMMENDATIONS 
HIV prevalence was high amongst women delivering in facilities in this Province in 
2007/2008. Anonymous cord blood studies together with clinical record documentation 
of PMTCT coverage and the infant dosing can be used to determine the effectiveness of 
PMTCT programs.  
PMTCT coverage in the Free State Province was poor despite the national expansion of 
PMTCT services to all antenatal sites. Failures occurred at each step of the PMTCT 
cascade and resulted in low coverage. Interventions should be introduced at each step of 
the PMTCT cascade to increase coverage. The number of antenatal care visits was 
associated with higher coverage and maternal adherence and women should be 
encouraged to attend antenatal care regularly.  
 Recommendations 
Further research is needed to determine the impact of implementing the new 
PMTCT protocol which consists of longer and more efficacious regimens on 
coverage.  
Train counsellors on how to deliver  high quality confidential counselling to 
improve testing coverage 
Improve HIV and PMTCT awareness through effective communication 
strategies and community engagement to decrease stigma towards people living 
with HIV and empower women on their reproductive rights. 
Offer repeat testing during late pregnancy to avoid women who seroconvert and 
women who receive false negative results from failing to receive PMTCT 
interventions 
Offer HIV testing during delivery and in the labour ward in addition to VCT 
during antenatal care for women who may refuse to test and those who do not 












Offer infant prophylaxis in blister packs together with adequate information on 
how to correctly store and administer the prophylaxis for women who wish to 
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